FDA approves sNDA for pediatric autism drug ABILIFY

20. November 2009 23:40

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. [More]

eb34af81-8141-4574-b270-52cb5d01cd03|0|.0

Posted in: Child Health News | Pharmaceutical News

Tags: Abilify, Antidepressant, Antipsychotic, Autism, Bipolar Disorder, Blood Pressure, Cardiovascular Disease, Cell, Cerebrovascular Disease, Constipation, Creatinine, Dehydration, Dementia, Depression, Diabetes, Diabetes Mellitus, Dystonia, Exercise, Heart Failure, Hyperglycemia, Hypersensitivity, Insomnia, Leukopenia, Lipids, Nausea, Neutropenia, New Drug Application, Obesity, Pediatrics, Pneumonia, Psychosis, Schizophrenia, Speech, Stroke, Tardive Dyskinesia, Urticaria, Vomiting

Swissmedic grants marketing authorization for Amitiza

20. November 2009 00:59

Sucampo Pharma Europe Ltd., a subsidiary of Sucampo Pharmaceuticals, Inc., today announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted a marketing authorization for Amitiza® (lubiprostone) 24 microgram (mcg) gel capsules for the long-term treatment of patients with chronic idiopathic constipation (CIC). [More]

613067d3-6076-4634-a8de-5abade95ce4d|0|.0

Posted in: Pharmaceutical News

Tags: Constipation, Diarrhea, Dyspnea, Irritable Bowel Syndrome, Lipids, Lubiprostone, Nausea, Pregnancy

Opiate-based painkillers can increase tumor-cell proliferation, says new study

19. November 2009 01:37

Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. [More]

93413953-874e-4748-8590-f191a2cb10c2|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anesthesiology, Angiogenesis, Brain, Cancer, Cell, Cell Proliferation, Constipation, Life Expectancy, Lung Cancer, Metastasis, Morphine, Non-Small Cell Lung Cancer, Prostate Cancer, Small Cell Lung Cancer

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

18. November 2009 10:31

Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March. [More]

a61a65ac-e150-48dc-bb4d-d91e79fc3c1c|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abdominal Pain, Anemia, Anorexia, Anxiety, Arthralgia, Blindness, Bone, Cancer, Cell, Constipation, Cough, Dehydration, Diarrhea, Doxorubicin, Dyspnea, Edema, Headache, Heart Failure, Herpes, Herpes Zoster, Hypersensitivity, Insomnia, Liposome, Lymphoma, Multiple Myeloma, Nausea, Neuropathy, Neutropenia, Nursing, Oncology, Peripheral Neuropathy, Pneumonia, Thrombocytopenia, Ubiquitin, Vomiting

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

18. November 2009 07:34

Pfizer Canada accepted the Prix Galien Canada 2009 Innovative Product Award for CHAMPIX (varenicline tartrate), the first prescription treatment for smoking cessation in adults specifically designed to target nicotine addiction. The award was presented last night at a gala in Ottawa recognizing excellence in pharmaceutical research. [More]

fca250df-5848-4337-8a95-05b6cd411164|0|.0

Posted in: Pharmaceutical News

Tags: Abstinence, Anxiety, Brain, Cardiovascular Disease, Constipation, Drug Abuse, Morphine, Nausea, Nicotine, Nicotine Addiction, Pfizer, Smoking, Smoking Cessation, Tobacco, Vomiting

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

18. November 2009 06:35

In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information. [More]

959d26c5-8d38-4083-a198-e232442942a6|0|.0

Posted in: Healthcare News

Tags: Cancer, Chemotherapy, Constipation, Diarrhea, Education, Lung Cancer, Nausea, Oncology, Vomiting

Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation

18. November 2009 04:10

Albireo today announced the completion of a phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate efficacy signals in this patient population. A3309 is a first in class compound developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C). [More]

e1963e02-da3f-4a4c-8957-9e1eb1ea7fd2|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Biotechnology, Constipation, Investment, Irritable Bowel Syndrome

Shire publishes new study results on INTUNIV Extended-Release Tablets

17. November 2009 04:21

Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication alone. [More]

f1905e57-99d9-420f-9a01-cfb46c853f5f|0|.0

Posted in: Child Health News | Pharmaceutical News

Tags: Abdominal Pain, Blood Pressure, CDC, Constipation, Headache, Hypersensitivity, Insomnia, Psychiatry, Psychopharmacology

Self-care tips for hemorrhoids from Mayo Clinic

16. November 2009 07:28

By about age 50, more than half of adults have dealt with hemorrhoids. The November issue of Mayo Clinic Health Letter covers home treatments that can relieve symptoms of this common and embarrassing problem. [More]

9465ab9b-175d-4e4b-8a93-4e668bc8d219|0|.0

Posted in: Medical Condition News

Tags: Acetaminophen, Aldosterone, Angiotensin, Blood Pressure, Cancer, Colonoscopy, Constipation, Defibrillator, Depression, Diabetes, Diarrhea, Heart Failure, Hydrocortisone, Ibuprofen, Inflammatory Bowel Disease, Lisinopril, Obesity, Parkinson's Disease, Pregnancy, Sleep, Sleep Apnea, Stress, Stroke

Home treatments for Hemorrhoids

16. November 2009 06:27

By about age 50, more than half of adults have dealt with hemorrhoids. The November issue of Mayo Clinic Health Letter covers home treatments that can relieve symptoms of this common and embarrassing problem. [More]

0b77e7bd-94e5-4a9d-94b5-9056b314d3d8|0|.0

Posted in: Medical Condition News

Tags: Acetaminophen, Cancer, Colonoscopy, Constipation, Diarrhea, Hydrocortisone, Ibuprofen, Inflammatory Bowel Disease, Obesity, Pregnancy

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

13. November 2009 01:18

Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS). [More]

b8bfc27c-e4f7-4931-bfab-38e1c3d4316b|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abdominal Pain, Arthritis, Autoimmune Disease, Biomarker, Constipation, Diabetes, Diarrhea, Glaucoma, Irritable Bowel Syndrome, Rheumatoid Arthritis, Serotonin, Tryptophan, Type 2 Diabetes

Adolor commences clinical testing of its oral mu opioid receptor antagonist

13. November 2009 00:42

Adolor Corporation today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010. [More]

8ef92f64-32e5-43d3-b1fd-43912469f050|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Abdominal Pain, Arthritis, Back Pain, Biotechnology, Constipation, Exercise, Opioids, Pfizer

Astellas receives exclusive rights to develop and commercialize linaclotide compound in Asia

10. November 2009 02:11

Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that they have entered into an agreement providing Astellas exclusive rights to develop and commercialize the investigational compound linaclotide in Japan, Indonesia, Korea, the Philippines, Taiwan, and Thailand. [More]

efd6c34c-fd8c-4c33-9b51-ec4be9b2d13b|0|.0

Posted in: Pharmaceutical News

Tags: Constipation, Immunology, Irritable Bowel Syndrome, Neuroscience, Oncology, Tacrolimus, Transplant, Urology

Shire's INTUNIV for treating ADHD now available in the U.S.

9. November 2009 10:26

Shire plc, the global specialty biopharmaceutical company, today announced the availability of INTUNIV(TM) (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17. [More]

b29f563f-5c95-4109-9b8a-07af74578511|0|.0

Posted in: Child Health News | Pharmaceutical News

Tags: Abdominal Pain, Blood Pressure, CDC, Constipation, Headache, Hypersensitivity, Psychiatry, Psychopharmacology

CRINONE vaginal progesterone gel as effective as IM progesterone for luteal phase support in IVF-ET

9. November 2009 08:50

In their American Society of Reproductive Medicine (ASRM) conference wrap-up, Medscape highlighted the article published by them on October 27, 2009, which summarized the results from the largest prospective, randomized clinical study to compare vaginal progesterone to intramuscular progesterone injections (IM progesterone) for luteal support in infertility treatment. [More]

eae6ffa9-f485-4ce6-8179-2b0c8cd4ba70|0|.0

Posted in: Women's Health News | Pharmaceutical News

Tags: Abortion, Constipation, Endocrinology, Exercise, Fertility, Headache, Hospital, Infertility, IVF, Menstruation, Nausea, Obstetrics, Ovulation, Pregnancy, Progesterone, Testosterone, Ultrasound

Free!

Recent Comments

Twitter

Information

Constipation News and Research

FDA approves sNDA for pediatric autism drug ABILIFY

Swissmedic grants marketing authorization for Amitiza

Opiate-based painkillers can increase tumor-cell proliferation, says new study

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Pfizer Canada accepts Prix Galien Canada 2009 Innovative Product Award for CHAMPIX

New source of information can help prescribers and patients in understanding anticipated side effects of treatments

Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation

Shire publishes new study results on INTUNIV Extended-Release Tablets

Self-care tips for hemorrhoids from Mayo Clinic

Home treatments for Hemorrhoids

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Astellas receives exclusive rights to develop and commercialize linaclotide compound in Asia

Shire's INTUNIV for treating ADHD now available in the U.S.

CRINONE vaginal progesterone gel as effective as IM progesterone for luteal phase support in IVF-ET

Recent Articles

Free!

Recent Comments

Twitter

Information

Constipation News and Research

Medical News Cloud

Recent Articles